Skip to main content
. 2012 Jun 12;4(3):475–480. doi: 10.3892/etm.2012.607

Figure 2.

Figure 2

Outcome according to the revised International Prognostic Index (R-IPI) for (A) progression-free survival and (B) overall survival in the 241 patients treated with chemotherapy alone and for (C) progression-free survival and (D) overall survival in the 197 patients who were treated with chemotherapy plus rituximab. CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHOP, rituximab plus the conventional CHOP regimen.